Book contents
- Frontmatter
- Contents
- List of Contributors
- Preface
- Part 1 Diagnostic techniques
- Part 2 Hematological malignancies
- 6 The integrated approach to the diagnosis of hematological malignancies
- 7 Acute lymphoblastic leukemia
- 8 Acute myeloid leukemia
- 9 Mature B-cell leukemias
- 10 Mature T-cell and natural-killer cell leukemias
- 11 Lymphoma
- 12 Plasma cell neoplasms
- 13 Chronic myeloid leukemia
- 14 Myeloproliferative neoplasms
- 15 Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
- Index
- References
12 - Plasma cell neoplasms
from Part 2 - Hematological malignancies
Published online by Cambridge University Press: 06 December 2010
Edited by
Book contents
- Frontmatter
- Contents
- List of Contributors
- Preface
- Part 1 Diagnostic techniques
- Part 2 Hematological malignancies
- 6 The integrated approach to the diagnosis of hematological malignancies
- 7 Acute lymphoblastic leukemia
- 8 Acute myeloid leukemia
- 9 Mature B-cell leukemias
- 10 Mature T-cell and natural-killer cell leukemias
- 11 Lymphoma
- 12 Plasma cell neoplasms
- 13 Chronic myeloid leukemia
- 14 Myeloproliferative neoplasms
- 15 Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
- Index
- References
Summary
Introduction
Plasma cell neoplasms result from the clonal expansion of terminally differentiated B-cells that have the capacity to secrete a monoclonal immunoglobulin (Ig). This chapter will discuss the appropriate use of diagnostic techniques in the diagnosis and assessment of multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell leukemia and Waldenström macroglobulinemia.
Multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of plasma cells (PC), mostly within the bone marrow (BM). The disease peaks in incidence in the seventh decade of life. While still considered an incurable diagnosis for most patients, patients are surviving longer due to the availability of new treatments. In a subset of patients, mostly those treated with more aggressive interventions such as combinations of novel agents and autologous stem cell transplant (SCT), the disease may be curable. MM is part of a spectrum of disorders characterized by this proliferation of clonal PC which includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). In MGUS, patients have a minimal plasmacytosis and the monoclonal PCs cause no harm to the individual; it is usually detected incidentally. Patients with MGUS can go on for years, often decades, without ever having further expansion of the monoclonal PCs. Patients with SMM have a more advanced plasmacytosis, yet have no discernible evidence of end organ damage due to this expansion.
- Type
- Chapter
- Information
- Diagnostic Techniques in Hematological Malignancies , pp. 244 - 265Publisher: Cambridge University PressPrint publication year: 2010
References
, . Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005;80(10):1371–82.CrossRefGoogle ScholarPubMed
, , et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23(6):1152–7.CrossRefGoogle Scholar
, , et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516–20.CrossRefGoogle ScholarPubMed
, , et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New Engl J Med 2006;354(10):1021–30.CrossRefGoogle ScholarPubMed
, , et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New Engl J Med 2002;346(8):564–9.CrossRefGoogle ScholarPubMed
, , et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New Engl J Med 2007;356(25):2582–90.CrossRefGoogle ScholarPubMed
, , et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?Hematol J 2000;1(1):28–36.CrossRefGoogle ScholarPubMed
, , et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20(9):1467–73.CrossRefGoogle ScholarPubMed
, , et al. Poor survival in plasmablastic myeloma in Eastern Cooperative Oncology Group study E9487: cell kinetic, ploidy, biological marker, and clinical correlations (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995;14.Google Scholar
, , et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99(5):1853–6.CrossRefGoogle ScholarPubMed
, , et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009;94(11):1599–602.CrossRefGoogle ScholarPubMed
, , et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009;114(20):4369–72.CrossRefGoogle ScholarPubMed
, , et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 2009;84(3):149–52.CrossRefGoogle ScholarPubMed
, , et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109(6):2276–84.CrossRefGoogle ScholarPubMed
, , , . The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985;66(2):380–90.Google ScholarPubMed
, , et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86(11):4250–6.Google Scholar
, , , , . Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98(7):2229–38.CrossRefGoogle ScholarPubMed
, , , . Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82(1):41–9.CrossRefGoogle ScholarPubMed
, , et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113(1):73–7.CrossRefGoogle Scholar
, , et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 1997;16(3):260–4.CrossRefGoogle Scholar
, , et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998;101(1):7–11.CrossRefGoogle ScholarPubMed
, , 2nd et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 1997;19(2):124–33.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
, , et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23(12):2210–21.CrossRefGoogle Scholar
, , et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003;17:2032–5.CrossRefGoogle Scholar
, , , , . Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003;101(4):1570–1.CrossRefGoogle Scholar
, , et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002;100(8):2996–3001.CrossRefGoogle ScholarPubMed
, , et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101(11):4569–75.CrossRefGoogle Scholar
, , et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12(2):131–44.CrossRefGoogle ScholarPubMed
, , et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12(2):115–30.CrossRefGoogle ScholarPubMed
, , et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9(4):313–25.CrossRefGoogle ScholarPubMed
, , et al. The molecular classification of multiple myeloma. Blood 2006;108(6):2020–8.CrossRefGoogle ScholarPubMed
, , , , . Prospective study of serum protein capillary zone electrophoresis and immunotyping of monoclonal proteins by immunosubtraction. Am J Clin Pathol 1998;110(4):503–9.CrossRefGoogle ScholarPubMed
, , et al. Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. Electrophoresis 1997;18(10):1775–80.CrossRefGoogle ScholarPubMed
, , , , . Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361(9356):489–91.CrossRefGoogle ScholarPubMed
, , et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48(4):655–7.Google ScholarPubMed
, . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842–54.3.0.CO;2-U>CrossRefGoogle Scholar
, , et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412–20.CrossRefGoogle ScholarPubMed
, , et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21(3):529–34.CrossRefGoogle ScholarPubMed
, , et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 2008;359(9):906–17.CrossRefGoogle ScholarPubMed
, , et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21(1):151–7.CrossRefGoogle ScholarPubMed
, , et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008;111(3):1603–9.CrossRefGoogle ScholarPubMed
. Is magnitude of initial response predictive for survival in multiple myeloma?Ann Oncol 1991;2(3):166.CrossRefGoogle ScholarPubMed
, , et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102(5):1115–23.CrossRefGoogle Scholar
, . Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983;62(1):166–71.Google ScholarPubMed
, , et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999;59(18):4546–50.Google ScholarPubMed
, , et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100(4):1417–24.Google ScholarPubMed
, , et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.[see comment]. Mayo Clinic Proceedings 2004;79(7):859–66.CrossRefGoogle Scholar
, , et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2009;148(1):110–4.CrossRefGoogle ScholarPubMed
, . Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987;83(6):1062–8.CrossRefGoogle ScholarPubMed
, , et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22(5):1044–52.CrossRefGoogle ScholarPubMed
, , et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97(3):822–5.CrossRefGoogle Scholar
, , et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93(3):1032–7.Google ScholarPubMed
, , . Waldenström's macroglobulinemia: laboratory diagnosis and treatment. Hematol Oncol 2000;18(2):41–9.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
, , . Defining Waldenström's macroglobulinemia. Semin Oncol 2003;30(2):107–9.CrossRefGoogle ScholarPubMed
, , et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 2002;132(1):55–60.CrossRefGoogle Scholar
, , et al. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006;169(2):150–3.CrossRefGoogle ScholarPubMed
, , et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenström's macroglobulinemia. Cancer Res 2009;69(8):3579–88.CrossRefGoogle ScholarPubMed
, , et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007;136(1):80–6.CrossRefGoogle ScholarPubMed